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Abstract
Background: The phosphodiesterase (PDE) 7 inhibitor S14 is a cell-permeable small heterocyclic molecule that is
able to cross the blood–brain barrier. We previously found that intraperitoneal treatment with S14 exerted
neuroprotection in an Alzheimer’s disease (AD) model (in APP/PS1 mice). The objective of this study was to
investigate the neurogenic and cellular effects of oral administration of S14 on amyloid β (Aβ) overload.
Methods: We orally administered the PDE7 inhibitor S14 (15 mg/kg/day) or vehicle in 6-month-old APP/PS1 mice.
After 5 weeks of S14 treatment, we evaluated cognitive functions and brain tissues. We also assessed the effects of
S14 on the Aβ-treated human neuroblastome SH-SY5Y cell line.
Results: Targeting the cyclic adenosine monophosphate (cAMP)/cAMP-response element binding protein (CREB)
pathway, S14 rescued cognitive decline by improving hippocampal neurogenesis in APP/PS1 transgenic mice.
Additionally, S14 treatment reverted the Aβ-induced reduction in mitochondrial mass in APP/PS1 mice and in the
human neuroblastoma SH-SY5Y cells co-exposed to Aβ. The restoration of the mitochondrial mass was found to be
a dual effect of S14: a rescue of the mitochondrial biogenesis formerly slowed down by Aβ overload, and a
reduction in the Aβ-increased mitochondrial clearance mechanism of mitophagy.
Conclusions: Here, we show new therapeutic effects of the PDE7 inhibitor, confirming S14 as a potential
therapeutic drug for AD.
Keywords: Phosphodiesterase, Alzheimer’s disease, Transgenic mice, Oral administration, Memory, Hippocampus,
Neurogenesis, Mitochondria, Mitophagy
Background
Alzheimer’s disease (AD) is the most common cause of
dementia and accelerates with advancing age. The most
prominent symptoms of the disease are the progressive
decline in cognitive functions and memory. AD is char-
acterized by three major neuropathological hallmarks:
senile plaques composed of amyloid β (Aβ) peptides,
intracellular neurofibrillary tangles, and neuronal loss.
The loss of neurons and synapses spreads to the hippo-
campus, entorhinal cortex, and frontal cortex, all of
which play important roles in reference and working
memory [1, 2]. In particular, the hippocampus is critical
for learning and memory as well as mood regulation,
and adult neurogenesis is necessary for its normal func-
tion [3, 4]. Adult hippocampal neurogenesis is known to
contribute to the processing and the storage of new
information [5, 6]. In AD brains the pathophysiological
environment could have adverse effects on neurogenesis
[7]. While memory deficits observed in AD could be
linked to alterations in hippocampal neurogenesis [8, 9]
we still need to actively investigate how neurogenesis is
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linked to cognitive function and whether stimulating re-
generative mechanisms in the brain could restore or pre-
vent further deterioration of cognition during the
disease process. During the process of synaptic strength-
ening and memory formation a variety of molecular
mechanisms are activated. The cyclic adenosine mono-
phosphate (cAMP)/cAMP-response element binding
protein (CREB) pathway may regulate the transcription
of genes controlling these processes. Many neurodegen-
erative diseases are associated with aberrant cyclic
nucleotide signalling related to phosphodiesterase (PDE)
expression. PDEs are key enzymes in the cAMP signal-
ling cascade. In AD brains, changes in cAMP-specific
PDE mRNA expression were detected [10, 11]. PDE7
inhibition has been implicated in inflammation and neu-
rodegenerative disorders [12, 13]. Peripheral administra-
tion of S14, a small heterocyclic molecule able to inhibit
the cAMP-specific PDE7, produced anxiolytic-like ef-
fects, restored visual short-term memory, and decreased
different pathological hallmarks in brains of APP/PS1
mice [14]. S14 treatment also induced in vitro and in
vivo proliferation of neural stem cells, promoting their
differentiation toward a dopaminergic phenotype in the
substantia nigra of hemiparkinsonian rats [15]. More re-
cently, the PDE7 inhibitor showed a significant increase
in newly generated neurons in the olfactory bulb and the
hippocampus of adult rats [16]. While PDE inhibitors
have demonstrated neurotrophic, neuroprotective, and
immunomodulatory potencies in AD models, little is
known about the role of PDE7 in hippocampal neuro-
genesis in AD and its effects on learning and memory.
Through activation of peroxisome proliferator-activated
receptor γ co-activator α (PGC-1α) and regulating p62
degradation, the cAMP/CREB pathway may also con-
trol mitochondrial dynamics and autophagy, respect-
ively [17–21]. Mitochondria are important organelles
in cells and more so in neurons since these demand
high amounts of energy for almost all cellular processes
including cell survival and death, calcium homeostasis
regulation, synaptic plasticity, and neurotransmitter synthe-
sis [22]. Mitochondrial dysfunction has been further dem-
onstrated in the pathogenesis of neurodegenerative
disorders [23–25] but not much is known about the inter-
action of PDE inhibition and mitochondrial dynamics in
neurodegeneration.
In this study, we evaluated the effects of oral ad-
ministration of S14 in APP/PS1 mice. Our results
demonstrated that S14 rescued memory deficits and in-
creased hippocampal neurogenesis mediated by upregula-
tion of the pCREB signalling pathway. Additionally, we
reported that S14 treatment restored the Aβ-induced
impairments in mitochondrial dynamics in APP/PS1 mice




S14 was synthesized in CIB-CSIC following previously de-
scribed procedures [26]. The compound was diluted in
0.5% w/v sodium carboxyl methyl cellulose (Na-CMC) and
0.1% v/v Tween 80 in water suspension. Pharmacokinetic
data for S14 showing a brain to plasma ratio oral bioavail-
ability of 0.2 and the effective dose for experiments of this
compound after oral administration calculated through
evaluation of brain and plasma levels of S14 have been pre-
viously reported [14].
Animal experiments
Male double transgenic APP/PS1 mice (6 months old), a
cross between Tg2576 (overexpressing human APP695)
and mutant PS1 (M146 L), were used from our inbred
colony (Instituto de Investigacion Hospital 12 de Octu-
bre). Age-matched mice not expressing the transgene
were used as wild-type controls. The PDE7 inhibitor S14
was orally administered in a 0.5% w/v sodium carboxyl
methyl cellulose (Na-CMC) and 0.1% v/v Tween 80 in
water suspension. For testing the effects of oral chronic
treatment on memory and neurogenesis, S14 (15 mg/kg)
or vehicle was given once per day for 5 weeks. At the
end of treatment, animals were deeply anaesthetised and
perfused transcardially either with saline for biochemical
analysis, or 4% paraformaldehyde (PFA) in 0.1 M phos-
phate buffer (PB), pH 7.4, for immunohistochemical ana-
lysis. All animals were handled and cared for according to
the Council Directive 2010/63/UE of 22 September 2010.
Measurement of learning and memory
Behavioural tests were performed 28 days after oral drug
administration following protocol A (Fig. 1a). An object
recognition test was performed as described previously
[27]. During this trial mice were placed individually in
the open field in the presence of a familiar object, and
the time spent exploring this object was measured.
During a 10-min retention trial (second trial), which was
performed 3 h later, a novel object was placed together
with the familiar object in the open field. The time the
animal spent exploring the two objects was recorded.
The recognition index, defined as the ratio of the time
spent exploring the novel object over the time spent
exploring both objects, was used to measure non-spatial
memory. Trials were recorded and tracked using the
Smart Video Tracking System (Panlab). Spatial memory
was tested using a Morris water maze for 4 consecutive
days, carrying out four trials of memory training each
day. Mice were allowed 60 s to reach the platform on
the opposite side of the channel. Mice were allowed to
stay on the platform for 15 s before being removed from
the water. The latencies were determined by measuring
the time to reach the platform. Twenty-four hours after
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the final trial, the platform was removed, and the mice
were given probe trials to test their memory of the hid-
den platform. Trials were recorded and tracked using
the Smart Video Tracking System (Panlab).
Evaluation of neurogenesis
Neurogenic effects of orally administered S14 were eval-
uated after 5-bromo-2′-deoxyuridine (BrdU; 50 mg/kg)
intraperitoneal injection once a day for 7 days, following
protocol B (Fig. 1a). On day 35, 21 days after the last
BrdU injection, the mice were anaesthetized with isofor-
ane and perfused transcardially with 4% PFA. Fixed
brains were cut on a vibratome (Leica Microsystems) at
40 mm, and tissue sections were collected in cold PB 0.1
M, and incubated overnight with primary antibodies at 4
°C. All primary antibodies were diluted in PB 0.1 M
containing 0.5% bovine serum albumin and 0.5% Triton
X-100. The following primary antibodies were used: rat
monoclonal anti-BrdU (1:20,000; Hybridoma Bank), goat
polyclonal anti-doublecortin (DCX; 1:500; Santa Cruz
Biotechnology), and mouse monoclonal anti-neuronal
nuclei (NeuN; 1:500; Millipore). After overnight incuba-
tion, primary antibody staining was revealed using the
avidin-biotin complex method (VECTASTAIN Elite
ABC Kit, Vector Laboratories, Burlingame, CA, USA) or
fluorescence-conjugated secondary antibodies from Mo-
lecular Probes. To estimate the total number of BrdU+
cells in the brain, we performed 3,3’-diaminobenzidine
(DAB) staining for BrdU on every sixth brain section.
The number of BrdU+ cells in the granule cell of the
dentate gyrus was counted using fluorescence micros-
copy (Zeiss microscope) at a magnification of 40× to es-
timate the total number of BrdU+ cells in the entire
dentate gyrus. Based on a modified stereological method
[28], BrdU+ were counted in one of every six sections
from rostral (2 mm from the bregma) to caudal (−4.3
mm from the bregma). To determine the fate of div-
iding cells, 100–150 BrdU+ cells across 4–6 sections
per mouse were analysed by fluorescence microscopy
co-localizing with NeuN (NeuN+). The number of
Fig. 1 Behavioural performance of APP/PS1 and wild-type (wt) mice after oral treatment with S14. a Protocol A: treatment schedule for memory testing.
Behavioural tests (BT) were carried out on days 28–35. S14 or vehicle (0.5% w/v Na-CMC and 0.1% v/v Tween 80 in water suspension) were orally adminis-
tered once per day for 5 weeks until the end of the tests (day 35) when the animals were sacrificed (SAC). Protocol B: treatment schedule for neurogenesis
testing. 5-Bromo-2’-deoxyuridine (BrdU) or saline was injected intraperitoneally (i.p.) on days 7–14. S14 or vehicle was orally administered once per day for
5 weeks until the end of the treatment (day 35) when the animals were sacrificed (SAC). b In the novel-object recognition test, APP/PS1 mice showed a
significant decline in performance. In APP/PS1 mice orally treated with S14 for 5 weeks, the ratio exploring the novel object was enhanced. Data are
expressed as mean ± SEM; n = 9–13 mice/group; *p < 0.05. c APP/PS1 mice exhibited impaired spatial memory in the Morris water maze test. d Latency
to reach the platform on the last day of training was higher in APP/PS1 mice. S14 treatment restored the spatial memory in APP/PS1 mice since latency to
reach the platform was similar to wild-type mice. Data are expressed as mean ± SEM; n = 9–13 mice/group; *p < 0.05. Statistical significance was assessed
by two-way ANOVA followed by Fisher’s post-hoc test for multiple comparisons. Veh vehicle
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double-positive cells was expressed as a percentage of
BrdU+ cells.
cAMP assay
Measurement of cAMP levels was determined by
enzyme-linked immunosorbent assay (ELISA) accord-
ing to the manufacturer’s instructions (Arbor Assays)
in brain tissue samples from APP/PS1 and wild-type
mice.
Immunoblot analysis
Proteins were isolated from brain tissue or cell cultures
by standard methods. Briefly, brain tissues or cell lysates
were homogenized in lysis buffer NP-40 (50 mM Tris-
base, pH 7.4, 150 mM NaCl, 0.5% Nonidet P-40, 1 mM
EDTA) containing a mixture of protease and phosphat-
ase inhibitors (Roche Applied Science) and centrifuged
for 15 min at 10,000 rpm at 4 °C. The supernatants were
collected, and the total protein concentrations were
measured by BCA assay (Pierce BCA Protein Assay Kit,
Thermo Fisher, Waltham, MA, USA); proteins from
each sample were loaded in a precast 4–20% Tris-
Glycine gels (Novex) and transferred to polyvinylidene
fluoride (PVDF) membranes (Bio-Rad). Primary anti-
bodies used were: rabbit polyclonal anti-pCREB (1:500,
Millipore), rabbit polyclonal anti-CREB (1:1000, Cell Sig-
nalling Technology), mouse anti-ATPasaβ (1:1000,
Abcam), rabbit anti-PGC-1α (1:200, Santa Cruz), mouse
anti-Mitofusin1 (Mfn1; 1:1000, Abcam), mouse anti-
Mitofusin2 (Mfn2; 1:1000, Abcam), mouse anti-β actin
horseradish peroxidase (HRP; 1:25,000, Abcam), mouse
anti-mitochondrial dynamin-like GTPase (OPA1; 1:1000,
Novus Biological), rabbit anti-Dynamin-related protein 1
(Drp1; 1:1000, Cell Signalling Technology), rabbit anti-
p62/SQSTM1 (1:20,000, Abcam), and rabbit anti-light
chain 3 (LC3; 1:1000, Novus Biological). Secondary
HRP-conjugated goat anti-mouse (1:5000, Sigma) and
goat anti-rabbit (1:5000, Life Technologies) were used.
Immunoreactive bands were visualized by enhanced
chemiluminescence (ECL; Pierce) and scanned on an
ImageQuant LAS 4000 (GE Healthcare).
Cell cultures
Human neuroblastoma (SH-SY5Y) cells were purchased
from the European Collection of Cell Cultures (Health
Protection Agency, Salisbury, UK) and maintained as
previously described [29]. Unless otherwise stated, SH-
SY5Y cells were seeded at a density of 4 × 104 cells/cm2
and maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% (v/v) fetal bovine
serum (FBS) and 2 mM L-glutamine at 37 °C and 5%
CO2. Cultures were incubated in fresh medium with or
without S14 (15 μM), and alone or in combination with
Aβ42 (1 μM). S14 was previously dissolved in dimethyl
sulfoxide (DMSO) and then diluted in a sterile culture
medium, as reported previously [30]. Aβ42 stock was
previously dissolved in acetic acid 0.1 M. Oligomeric
Aβ42 was prepared by incubating a volume of stock solu-
tion in DMEM at 4 °C for 24 h prior to addition to the
cell cultures as previously described [31].
Primary cortical neuronal cultures
Pregnant Wistar rats (3–5 months) were obtained from
the inbred colony of the Research Institute, Hospital
Doce de Octubre, Madrid, Spain. Primary cortical neur-
onal cultures were prepared from rat embryos (E15–16)
based on methods previously described [32], and 4 × 105
cells per well were plated on poly-L-lysine-coated cover-
slips in six-well plates. Cells were maintained at 37 °C in a
5% CO2 humidified atmosphere in Neurobasal A medium
(Gibco) containing 2 mM L-glutamine, and 10% B27
Supplement (Invitrogen). Nine days after cell culture prep-
aration, cortical neurons were treated with or without S14
(15 μM), alone or in combination with oligomerised Aβ42
(1 μM). All live cell imaging experiments were performed
between days 10 and 14 in culture. All animals were han-
dled and cared for according to the Council Directive
2010/63/UE of 22 September 2010.
Mitochondrial mass assessment
To measure mitochondrial mass (mitochondrial vol-
ume as a percentage of cell volume in living cells) 40
min before the experiment, SH-SY5Y cells were
loaded with Cell Trace Calcein-AM (Invitrogen) to
visualise the whole cell volume and tetramethyl-
rhodamine methylester (TMRM) to visualise the mito-
chondria inside each cell. High-resolution Z-stacks
were acquired for approximately 15 cells per group
using a confocal Zeiss 510 microscope equipped with
a META detection system and a 63× oil immersion
objective with an excitation/emission of 495/515 nm
for calcein and 560/580 nm for TMRM. As TMRM is
mitochondrial membrane potential dependent, the
setting to detect red fluorescence was reduced to lo-
calise mitochondria still not degraded. Image analysis
was carried out using Volocity software (PerkinElmer,
Waltham, MA, USA) to measure the mitochondrial
and cytosolic volume.
Statistical analysis
Results are expressed as mean ± standard error of the mean
(SEM). Statistical analyses were performed using a two-way
analysis of variance (ANOVA) followed by Fisher’s post-hoc
test for multiple comparisons. All calculations were made
using GraphPad Prism6 software. Statistical significance
was set at p < 0.05.
Bartolome et al. Alzheimer's Research & Therapy  (2018) 10:24 Page 4 of 15
Results
Oral S14 treatment restored memory disturbances in
APP/PS1 mice
Memory functioning was assessed in 6-month-old trans-
genic APP/PS1 and wild-type mice using two different be-
havioural tests. In the object recognition test, recognition
index was significantly impaired in APP/PS1 mice com-
pared to wild-type mice (p < 0.05; Fig. 1b). S14-treated
APP/PS1 mice showed restoration of the impaired cogni-
tion similar to the wild-type group. Note that S14 admin-
istration in wild-type mice did not significantly alter
behaviour. In the Morris water maze paradigm, APP/PS1
mice displayed significant spatial learning impairment
compared with their littermate controls (p < 0.05; Fig. 1c),
while S14-treated APP/PS1 mice were completely rescued
from this impairment. Mice treated with this drug
candidate displayed reductions in the latency to
reach the hidden platform that was similar to those
of wild-type controls during the probe test, suggest-
ing that S14 induced an improvement in spatial
memory (Fig. 1c). To further elucidate these differ-
ences, an additional analysis was conducted, compar-
ing the latencies to reach the platform on the last
day of training (Fig. 1d), demonstrating a significant
overall difference among the groups (p < 0.05), with
complete reversal of the memory impairment in S14-
treated APP/PS1 mice (compared to wild-type mice).
Oral S14 treatment enhanced hippocampal cell
proliferation and neurogenesis in APP/PS1 mice
The association between cognitive deterioration and de-
cline in neurogenesis during aging, coupled with disrup-
tion in neurogenesis and cognitive dysfunction in AD
mouse models, suggests that enhancing neurogenesis may
be a feasible therapeutic approach. Thus, we explored the
effects of S14 on hippocampal neurogenesis in mice sacri-
ficed 21 days after the last BrdU injection. Positive BrdU
cells (BrdU+) were predominantly localised in the sub-gra-
nular cell layer and, to a less extent, in the hilus (Fig. 2a).
S14 treatment for 5 weeks significantly increased the num-
ber of BrdU+ cells in the dentate gyrus in APP/PS1 mice
when compared with vehicle-treated mice (p < 0.01; Fig. 2b).
Then the specific rate of new-born neurons in adult mice
was evaluated in brain sections from S14- and vehicle-
treated wild-type and APP/PS1 mice processed for dual-
labelling immunohistochemistry with antibodies against
BrdU and the neuronal-specific marker NeuN (Fig. 2c, d).
Co-localisation analysis revealed that the number of BrdU+
neurons was significantly higher in both groups of S14-
treated mice. Although the neurogenesis rate was found to
be increased even in the wild-type group (p < 0.05), the
neurogenesis was much higher in the APP/PS1-treated mice
(p < 0.01; Fig. 2d).
S14 treatment activates the hippocampal cAMP/pCREB
pathway
It is known PDE7 inhibitors activate the cAMP-dependent
pathway [14, 33]; therefore, we examined the levels of
cAMP and CREB activation (phospho-CREB, or pCREB) in
the hippocampus from the different mice groups to probe
the target engagement of S14 and the link with the ob-
served higher rate of neurogenesis. We found that S14
treatment increased cAMP accumulation in both wild-type
(p < 0.05; Fig. 3a) and APP/PS1 mice (p < 0.01; Fig. 3a), in-
dicating that this compound reached both the target and
the brain. A significant decrease in the phosphorylation sta-
tus of CREB was found in the hippocampus of APP/PS1
mice compared to the wild-type group, showing no changes
in the total CREB protein levels (p < 0.05; Fig. 3b, c).
Conversely, S14 treatment increased the phosphorylation
status of CREB in the hippocampus of both groups com-
pared to vehicle-treated mice (Fig. 3b, c) showing no
changes in the total CREB protein levels. As pCREB may
be considered a surrogate biomarker of cAMP increasing,
the enhancement of pCREB in the treated animals confirms
that oral administration of S14 targets the cAMP-specific
PDE7 pathway in the hippocampus.
S14 treatment increases the PGC-1α levels and the
mitochondrial biogenesis in the hippocampus of APP/PS1
mice and in Aβ-treated SH-SY5Y cells
PGC-1α is a downstream effector of CREB activation. The
levels of PGC-1α in the hippocampus of APP/PS1 mice
tended to be reduced when compared to wild-type mice,
but the difference was not statistically significant (Fig. 4a).
S14 treatment, however, induced an increase in PGC-1α
levels in APP/PS1 mice (Fig. 4a). PGC-1α is a master
regulator of mitochondrial biogenesis and dynamics;
therefore, we investigated the effect of S14 treatment on
the mitochondrial biogenesis in wild-type and APP/PS1
mice in the hippocampus. To verify whether PGC-1α
down- and upregulation by Aβ and S14, respectively,
could cause changes in mitochondrial mass, we estimated
the amount of total mitochondrial mass by analysing the
levels of the representative mitochondrial protein complex
V β subunit (CxVβ) using immunoblotting (Fig. 4b).
Quantified Western blots revealed a significantly reduced
amount of mitochondrial mass in APP/PS1 mice
compared to the wild-type group (p < 0.05; Fig. 4b). S14
treatment restored the mitochondrial mass in APP/PS1
mice with no effects on wild-type mice (p < 0.05; Fig. 4b).
Further evaluation of the effect of S14 on the mitochon-
drial mass was carried out in live cells using the human
neuroblastoma SH-SY5Y cell line and rat primary cortical
neurons. Cells were simultaneously exposed to 1 μM olig-
omeric Aβ42 for 24 h and mitochondrial mass was evalu-
ated by confocal imaging (Fig. 4c, d, and Additional file 1:
Figure S1). Imaging analysis revealed a reduced amount of
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mitochondrial volume from the whole cell volume in Aβ42-
exposed cells compared to untreated cells (p < 0.01; Fig. 4d)
in both SH-SY5Y cells and primary neuronal cultures. S14
treatment on Aβ42-exposed cells avoided this effect, show-
ing no changes on those cells not exposed (p < 0.05; Fig. 4d
and Additional file 1: Figure S1). Immunoblotting experi-
ments on SH-SY5Y cells confirmed a reduced number of
mitochondria, estimated by analysis of CxVβ levels, in SH-
SY5Y cells exposed to oligomeric Aβ42 compared to
untreated cells, and this effect was restored upon S14 treat-
ment (p < 0.0001; Fig. 4e). Additionally, PGC-1α levels were
found to be reduced in cells exposed to Aβ42 compared to
untreated cells (p < 0.01), whereas co-administration
with S14 completely abolished the Aβ42-induced effect
(p < 0.001; Fig. 4f ). In agreement with the above re-
sults, the PDE7 inhibitor S14 restored the damaged
mitochondrial biogenesis due to Aβ overload as dem-
onstrated in the APP/PS1 mice and SH-SY5Y cells.
S14 treatment modulates Aβ-induced effects on
mitochondrial fusion and fission processes
A combination of mitochondrial biogenesis, mitochon-
drial fusion/fission, and mitochondrial degradation is
reflected in the amount and distribution of mitochondria
in cells. As we have demonstrated, S14 can rescue the dis-
rupted rate of mitochondrial biogenesis by Aβ overload
we also answered whether PDE7 inhibition could induce
changes in the fusion/fission mitochondrial quality control
processes. Mitofusins 1 and 2 (Mfn1 and Mfn2, respect-
ively) in the outer mitochondrial membrane and optic
atrophy 1 (Opa1) in the inner mitochondrial membrane
regulate the fusion process, and the dynamin-related
Fig. 2 S14 treatment enhances hippocampal cell proliferation and neurogenesis in APP/PS1 mice. a Representative images showing 5-bromo-2’-
deoxyuridine-positive (BrdU+) cells in the dentate gyrus (DG) in wild-type (wt) and APP/PS1 mice. Scale bar = 20 μm. b Quantification of BrdU+
cells showing higher cell proliferation in S14-treated APP/PS1 mice compared to vehicle (Veh)-treated mice. Data are expressed as mean ± SEM; n
= 9–13 mice/group; **p < 0.01. c Representative images showing BrdU+/neuronal nuclei (NeuN)+ cells in the dentate gyrus in wild-type and APP/
PS1 mice. Scale bar = 20 μm. d Quantification of BrdU+/NeuN+ cells showing a significant increase in neurogenesis in both S14-treated mice
groups compared to vehicle-treated mice. Data are expressed as mean ± SEM; n = 9–13 mice/group; *p < 0.05; **p < 0.01. Statistical significance
was assessed by two-way ANOVA followed by Fisher’s post-hoc test for multiple comparisons
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protein 1 (Drp1) regulates the mitochondrial fission.
A reduction in Mfn1, Mfn2, and Opa1 levels, as well
as increased levels in Drp1, could indicate an
increased rate of mitochondrial fission degradation.
SH-SY5Y cells exposed to oligomeric Aβ42 showed re-
duced mitochondrial fusion proteins levels (Mfn1,
Mfn2, and Opa1) and increased levels of the mito-
chondrial fission protein Drp1 (Fig. 5a, b). S14 treat-
ment on SH-SY5Y cells exposed to Aβ42 rescued the
levels of these proteins to values similar to those of
the untreated cells (Fig. 5a, b). Upon mitochondrial
damage, the outer mitochondrial membrane mitofu-
sins are substrates for ubiquitination, increasing the
mitochondrial fission rate. We therefore used the ubi-
quitination of Mfn1 and Mfn2 as a readout for activa-
tion of mitophagy in the hippocampus of the APP/
PS1 mice. The ubiquitination pattern of mitofusins in
transgenic mice was enhanced compared to wild-type
mice (Fig. 5c). Accordingly, the levels of Opa1 were
reduced and the Drp1 protein levels were found to be
increased in APP/PS1 mice (p < 0.05; Fig. 5d, e). S14
treatment reduced the ubiquitination of Mfn1 and
Mfn2 and significantly restored the Opa1 and Drp1 pro-
tein levels restoring them to wild-type values (p < 0.05;
Fig. 5c–e). In summary, the PDE7 inhibitor S14 could res-
cue the mitochondrial fusion/fission balance previously
impaired upon Aβ overload exposure.
S14 treatment modulates Aβ-induced effects on
mitophagy
Ubiquitination of mitochondrial profusion proteins
and increased levels of mitochondrial profission pro-
teins may result in autophagic clearance of damaged
mitochondria. Since the PDE7 inhibitor S14 rescued
the Aβ-induced mitochondrial fusion/fission imbal-
ance, we further investigate its effect on subsequent
mitophagy. During induction of autophagy, LC3-I is
lipidated on its mature form, LC3-II, which localizes
to the autophagosome as it engulfs the substrate for
degradation [34]. Immunoblotting revealed that Aβ42
exposure resulted in elevated LC3-II levels compared
to untreated cells (p < 0.01; Fig. 6a, b). A similar ef-
fect was observed in APP/PS1 mice compared to the
wild-type group (p < 0.05; Fig. 6c, d). S14 treatment
in cells and APP/PS1 mice restored the LC3-II levels
to similar values to untreated cells (p < 0.0001), and
wild-type mice (p < 0.001), respectively. Another pro-
tein, p62, anchors both the exposed LC3-II in the
phagophore (preformed autophagosome) and the
damaged mitochondria prompted to be degraded;
therefore, increased levels of p62 are also distinctive
of autophagy. Immunoblotting carried out in SH-
SY5Y cells showed that Aβ42 exposure induced a sig-
nificant increase in p62 levels compared to untreated
cells (p < 0.001; Fig. 6a, b), and a similar effect was
Fig. 3 cAMP and pCREB levels in the hippocampus are increased after PDE7 inhibition in APP/PS1 and wild-type mice. a Cyclic adenosine
monophosphate (cAMP) levels in the hippocampus of both S14-treated mice groups compared to untreated mice. Data are expressed as mean ±
SEM; n = 6–7 mice/group; *p < 0.05; **p < 0.01. b,c Representative immunoblots and quantified levels of phosphorylated (p) and total cAMP-
response element binding (CREB) protein. pCREB levels were reduced in the hippocampus of APP/PS1 mice, whereas S14 treatment increased
pCREB expression in wild-type (wt) and APP/PS1 mice compared with vehicle-treated groups. Levels of total CREB remained unchanged. Data are
expressed as mean ± SEM; n = 6–7 mice/group; *p < 0.05; **p < 0.01. Statistical significance was assessed by two-way ANOVA followed by Fisher’s
post-hoc test for multiple comparisons. Veh vehicle
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found in the APP/PS1 mice compared to wild-type mice
(p < 0.05; Fig. 6c, d). S14 treated cells co-exposed to Aβ42
exhibited similar levels of p62 to those from untreated
cells (p < 0.001; Fig. 6a, b). PDE7 inhibitor treatment in
mice induced a high reduction in the p62 levels in both
wild-type and APP/PS1 mice, but the reduction in this
Fig. 4 Amyloid β (Aβ)-induced reduction on mitochondrial biogenesis is restored after S14 treatment. a Upper panel shows representative Western
blot bands, and the lower panel shows increased peroxisome proliferator-activated receptor γ co-activator α (PGC-1α) expression in the hippocampus
of S14-treated APP/PS1 mice compared with the vehicle (Veh)-treated group (n = 5–7 mice per group; *p < 0.05). b Representative immunoblots
(upper panels) and protein level quantification detected by Western blot (lower panel) showing a significant reduction in the expression of complex V
β subunit (CxVβ) in the hippocampus of S14-treated APP/PS1 mice compared with the vehicle-treated group (n = 5–7 mice per group; *p < 0.05).
When transgenic mice were treated with S14, CxVβ levels were recovered. Data are expressed as mean ± SEM. c Mitochondrial mass was measured in
live cells using the human neuroblastome SH-SY5Y cell line simultaneously exposed to 1 μM oligomeric Aβ42 for 24 h and evaluated by confocal
imaging. d Imaging analysis revealed a reduced amount of mitochondrial volume from the whole cell volume in Aβ42-exposed cells compared to
untreated cells. Treatment with 15 μM S14 on Aβ42-exposed cells obliterated this effect, showing no changes on the unexposed cells. Data are
expressed as mean ± SEM; n = 4; *p < 0.05; **p < 0.01. e,f Representative immunoblots (upper panel) and quantification of the measures detected by
Western blot (lower panel) showing a significant reduction in the CxVβ levels (e) and PGC-1α (f) in SH-SY5Y cells exposed to 1 μM oligomeric Aβ42.
When cells were co-treated with 15 μM S14, CxVβ (e) and PGC-1α (f) expression were recovered. Data are expressed as mean ± SEM; n = 4; **p < 0.01;
***p < 0.001; ****p < 0.0001. Statistical significance was assessed by two-way ANOVA followed by Fisher’s post-hoc test for multiple comparisons.
wt wild-type
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was much higher in APP/PS1 mice whose p62 levels
in the hippocampus were found to be 1.5-fold higher
than in wild-type mice. This could be related to the
increased cAMP observed in both wild-type and APP/
PS1 mice since cAMP could upregulate p62 degrad-
ation (p < 0.001; Fig. 6c, d). In summary, the above
results could indicate that S14 treatment abolished
the Aβ-induced mitophagy by reducing the p62 levels
and LC3 lipidation.
PDE7 inhibition upregulates mitochondrial biogenesis
and mitophagy in the cerebral cortex from APP/PS1 mice
Recognition memory control is typically attributed to the
hippocampus, but the cerebral cortex is also controlling
this process. Therefore, we investigated if S14 could inter-
fere in mitochondrial dynamic alterations in the same way
as it is interfering in the hippocampus. We confirmed that
S14 also induced a twofold increase in cAMP levels in cor-
tical samples from APP/PS1 (untreated APP/PS1 = 0.61
Fig. 5 PDE7 inhibition modulates amyloid β (Aβ)-induced effects on mitochondrial fission, and fusion protein levels. a Immunoblots and b
densitometric analysis of mitochondrial fission and fusion proteins in SH-SY5Y cells exposed to 1 μM oligomeric Aβ42. The fusion proteins
mitofusin1 (Mfn1), mitofusin2 (Mfn2), and optic atrophy 1 (Opa1) were reduced in SH-SY5Y cells exposed to 1 μM oligomeric Aβ42. When
cells were co-treated with S14, the expression of all these fusion proteins was recovered. Dynamin-related protein 1 (Drp1) levels were
significantly increased in Aβ42-treated SH-SY5Y cells, and those levels were restored after co-administration of 15 μM S14. Data are
expressed as mean ± SEM; n = 5–7; *p < 0.05; **p < 0.01; ***p < 0.001. c In the transgenic APP/PS1 mice, the ubiquitination pattern of
mitofusins was enhanced compared to wild-type (wt) mice and S14 treatment abolished this ubiquitination. Whereas d Opa1 levels were
reduced, e Drp1 expression was increased in the hippocampus of APP/PS1 and wild-type mice. S14 treatment restored these protein
levels to those observed in wild-type mice. Data are expressed as mean ± SEM; n = 3–6 mice; *p < 0.05. Statistical significance was
assessed by two-way ANOVA followed by Fisher’s post-hoc test for multiple comparisons. Veh vehicle
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pmol/ml; APP/PS1 + S14 = 1.13 pmol/ml; n = 4 mice/
group). The analysis of CxVβ protein levels revealed re-
duced mitochondrial mass in cortical lysates from APP/
PS1 mice compared to wild-type mice (Fig. 7a). The re-
duction in the mitochondrial mass in APP/PS1 mice was
subsequently related to a reduction in the mitochondrial
biogenesis reflected in reduced PGC-1α levels compared
to the wild-type group (p < 0.05; Fig. 7b) and imbalances
in the mitochondrial fusion/fission events as demon-
strated by increased ubiquitination of Mfn1 and Mfn2, re-
duced levels of Opa1 (p < 0.01), and increased levels of
Drp1 (p < 0.05) in APP/PS1 mice compared to wild-type
mice (Fig. 7c–e). S14 treatment did not significantly res-
cue the reduced mitochondrial mass in the cerebral cortex
from APP/PS1 mice; however, the PGC-1α levels, the ubi-
quitination pattern of Mfn1 and Mfn2, and the Opa1 and
Drp1 levels in APP/PS1 mice were significantly restored
to equivalent values to the wild-type group (Fig. 7a–e).
Equivalent to the effect observed in hippocampus,
S14 treatment significantly reduced the p62 levels in
both wild-type and APP/PS1 mice but this reduction
was much more significant in APP/PS1 mice whose
p62 levels in the cortex were found to be 1.8-fold
higher than wild-type mice (Fig. 7f ). The LC3-I lipi-
dation to LC3-II was found to be increased in the
cortex from APP/PS1 mice (p < 0.05) compared to
wild-type mice, and S14 treatment attenuated this
effect in APP/PS1 mice (Fig. 7g). The above results
may indicate that the PDE7 inhibitor S14 could
ameliorate the behavioural impairments induced by
Aβ overload in the cerebral cortex of the APP/PS1
mice by interfering in the mitochondrial dynamics.
Discussion
n this study, we investigated the effects of oral ad-
ministration of the small heterocyclic molecule S14
on the neuronal and cognitive features of AD. We
report here that inhibition of PDE7 reversed hippo-
campal and cortical Aβ-induced memory impairments,
restored CREB phosphorylation via increasing intra-
cellular cAMP levels, and increased the hippocampal
neurogenesis in transgenic APP/PS1 mice. We also
find that co-administration of S14 abolished the Aβ-
induced mitochondrial dynamic impairments.
Our results showed that S14 was able to restore
learning and memory deficits in APP/PS1 mice as
shown by a reduced latency to reach the hidden plat-
form in the Morris water maze. Consistent with our
previous studies using intraperitoneal administration
[14], oral treatment with S14 also improved non-
spatial visual recognition memory measured in the
object recognition test. Inhibitors of PDE7 have
proven to be effective experimental drugs for explor-
ing cognitive and motor recovery [14, 35–37].
Fig. 6 S14 treatment modulates amyloid β (Aβ)-induced effects on autophagic markers. a Representative Western blot and b estimated
p62 and light chain 3 (LC3)-II protein levels in SH-SY5Y cells. Protein level analysis revealed a significant increase in p62 and LC3-II levels
in SH-SY5Y cells exposed to 1 μM oligomeric Aβ42. When cells were co-treated with 15 μM S14, p62 and LC3-II levels were recovered.
Data are expressed as mean ± SEM; n = 6; **p < 0.01; ***p < 0.001; ****p < 0.0001. c Representative Western blot and d estimated p62
and LC3-II protein levels in the hippocampus of APP/PS1 and wild-type (wt) mice. p62 and LC3-II protein levels were found increased in
the hippocampus of APP/PS1 mice and S14 treatment was able to restore both to those observed in wild-type mice. Data are expressed
as mean ± SEM; n = 3–7 mice; *p < 0.05; ***p < 0.001. Statistical significance was assessed by two-way ANOVA followed by Fisher’s post-
hoc test for multiple comparisons. Veh vehicle
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We provide several new insights into the mechanisms
of S14-enhanced hippocampal neurogenesis and mem-
ory in APP/PS1 mice. The hippocampus is a key brain
structure for learning and memory and one of the main
brain regions to be affected in AD, which arises on the
pathological background of Aβ burden, neurofibrillary
tangles, and synaptic and neuronal loss [38]. Although
decreased neurogenesis is generally thought to be re-
sponsible for learning and memory impairments in AD,
it is somewhat controversial whether neurogenesis is
decreased or increased in the context of AD [39–42].
Here, we show that neurogenesis was not significantly
different in the dentate gyrus of 6-month-old APP/PS1
mice compared to the wild-type group as assessed by
BrdU+/NeuN+ staining. However, S14 treatment was
found to upregulate neurogenesis in the dentate gyrus of
these animals; this was much more increased in the
transgenic mice. The observed memory improvements
in APP/PS1 mice may be related to the subsequent in-
crease in intracellular cAMP and pCREB levels that we
Fig. 7 S14 treatment restores mitochondrial protein levels in the cerebral cortex in APP/PS1 mice. a Representative immunoblots (upper panels)
and protein level quantification detected by Western blot (lower panel) showing a significant reduction in the complex V β subunit (CxVβ) levels
in the cerebral cortex from APP/PS1 mice compared to the wild-type (wt) group. When transgenic mice were treated with S14, CxVβ levels were
slightly but not significantly recovered (n = 3–5 mice per group; *p < 0.05). b Representative Western blot bands (upper panel), and quantified
levels detected by Western blot (bottom panel) showing a significant reduction in Peroxisome proliferator-activated receptor γ co-activator α
(PGC-1α) levels in the cerebral cortex from APP/PS1 mice compared with the wild-type group. When transgenic mice were treated with S14,
PGC-1α levels were recovered. Data are expressed as mean ± SEM (n = 4–5 mice per group; *p < 0.05; ***p < 0.001). c Ubiquitination pattern of
mitofusins in cerebral cortex from mice. S14 treatment restored the observed increased ubiquitination of mitofusin1 (Mfn1) and mitofusin2 (Mfn2)
in the APP/PS1 transgenic mice. d Representative Western blot and e estimated optic atrophy 1 (Opa1) and dynamin-related protein 1 (Drp1)
protein levels in the cortex from APP/PS1 and wild-type mice. Opa1 protein levels were found to be reduced and Drp1 levels were found to be
increased in APP/PS1 mice. S14 treatment was able to restore both to those observed in wild-type mice. Data are expressed as mean ± SEM;
n = 3–6 mice per group; *p < 0.05; ***p < 0.001. f Representative Western blot and g estimated p62 and light chain 3 (LC3)-II protein levels in the
cortex from APP/PS1 and wild-type mice. p62 and LC3-II protein levels were found to be increased in the cerebral cortex from APP/PS1 mice, and
S14 treatment was able to restore both to those observed in wild-type mice. Data are expressed as mean ± SEM; n = 3–5 mice per group;
*p < 0.05; **p < 0.01; ****p < 0.0001. Statistical significance was assessed by two-way ANOVA followed by Fisher’s post-hoc test for multiple
comparisons. Veh vehicle
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found in the cortex and hippocampus after PDE7 inhib-
ition using S14. CREB is a key regulator of differenti-
ation and maturation in adult neurogenesis [43] and its
activation by phosphorylation leads to transcription of
memory-associated genes as a hub of pathways and
mechanisms activated during the processes of synaptic
strengthening and memory formation [44]. Disruption of
these mechanisms in AD results in reduced CREB acti-
vation and memory impairments [45]. Decreased activa-
tion of CREB in our APP/PS1 mice and its re-
establishment after chronic oral treatment with S14 in
the cortex and hippocampus suggest that the cAMP/
CREB cascade may be involved in the protective role of
S14 on synaptic strengthening and memory improve-
ment/enhancement/long-term potentiation (LTP) mem-
ory, in agreement with new therapeutic strategies based
on the use of drugs enhancing CREB activation [46].
Our findings show that S14 treatment rescued the re-
duced mitochondrial mass in both Aβ-treated SH-SY5Y
cells and APP/PS1 mice. Reduced mitochondrial mass has
already been found in brains from AD patients compared
to healthy controls in a mouse model of AD and in AD
cellular models [47–49]. A reduction in the number of
mitochondria could be a consequence of impairments in the
mitochondrial biogenesis or enhanced mitochondrial-specific
autophagy clearance known as mitophagy. Activation of the
cAMP/CREB pathway resulting in the phosphorylation of
CREB contributes to enhance the transcription of the PGC-
1α promoter, a key regulator of mitochondrial biogenesis
[19, 20]. Our data showed that S14 treatment increased
PGC-1α levels, reversing the Aβ-mediated reduction in
mitochondrial biogenesis. Aβ-induced decreased mitochon-
drial biogenesis has been found previously by other authors
[50, 51]. Additional studies show that mitochondrial DNA
copy number and the expression levels of PGC-1α were sig-
nificantly reduced in brains from AD patients and transgenic
mouse models of AD, suggesting impaired mitochondrial
biogenesis [23, 52–55]. Mitochondria are essential in adult
neurogenesis, including having a modulatory function over
maturation of adult-born hippocampal neurons [56]. Tran-
scriptional pathways may not only control the expression of
neuron-specific genes but may also target mitochondrial bio-
genesis. In this regard, the transcription factor CREB may
fulfil coordinative functions given that its target, PGC-1α,
has been linked with the control of cell maturation in hippo-
campal neurons [57]. It is reasonable that S14 treatment, by
improving neurogenesis in APP/PS1 mice, simultaneously
induces mitochondrial biogenesis since mitochondria are the
power houses of neurons, providing energy for cytoskeletal
remodelling, outgrowth of neuronal processes, growth cone
activity, and synaptic activity. The number of mitochondria
may also be controlled by mitophagy, a tightly regulated
process in which damaged or non-functional mitochondria
are separated from the mitochondrial network and prompted
for degradation. We showed that Aβ treatment shifted
the fusion/fission balance towards increased fission.
The PDE7 inhibitor S14 restored the Aβ-reduced
levels of the mitochondrial profusion proteins Mfn1,
Mfn2, and Opa1, and, conversely, it rescued the
Aβ-increased levels of the fission protein Drp1. Aβ
treatment shifted the fusion/fission balance towards
increased fission. A balance between the mitochon-
drial levels of these fusion/fission proteins is essential
to maintain a functional mitochondrial network in the
cells. This has been further demonstrated in brains
from AD patients and mouse and cellular models of
AD related to Aβ deposition [58, 59]. Based on the
Aβ accumulation effect, our results link PDE7 inhib-
ition and downstream signalling with a restoration of
the fusion/fission protein levels. Additionally, Mfn2,
whose expression is induced by PGC-1α, regulates
not only the mitochondrial fusion but also mitochon-
drial biogenesis and mitochondrial function through
changes in mitochondrial membrane potential and the
expression of OXPHOS subunits [60].
Finally, we have demonstrated PDE7 inhibition abol-
ished the Aβ-induced mitophagy by reduction in LC3-II
and p62 levels previously increased as a consequence of
misbalances on mitochondrial fusion/fission events after
Aβ exposure/overload. Mitofusin ubiquitination induces
their proteasomal degradation and subsequently reduces
the mitofusin levels. This, along with reduced Opa1 and
increased Drp1 levels, triggers the split of damaged
mitochondria from the mitochondrial network. At the
same time, ubiquitination of mitochondrial proteins tar-
gets the mitochondria to be engulfed by autophagosome
membranes showing increased lipidated LC3 (LC3-II)
levels. p62 protein anchors the targeted mitochondria to
the autophagosome membranes. Previous work has
shown reduced autophagy rates in several disease
models by PDE inhibition. In particular, p62 degradation
has been found to be increased in several works analys-
ing the effects of antioxidants on autophagy [17, 21]. In
these studies, authors reported increased levels of cAMP
regulating the increased degradation of p62, thus redu-
cing p62 levels. In 2015, Boland et al. simultaneously
inhibited most PDE isoforms targeting the cAMP/CREB
pathway by using classical inhibitors of autophagy [61].
They observed that this treatment increased the cAMP
in pancreatic cells, increasing the insulin production that
was formerly deteriorated [61]. In other work, Hosokawa
et al. reported that PDE5 inhibition restored the
increased autophagy rates in a muscle weakness mouse
model [62]. We can conclude that S14 treatment reduces
the previously Aβ-increased mitophagy rates. It is known
that Aβ induces mitophagy, as has been demonstrated in re-
cent studies [58, 59]. We can speculate that PDE7 inhibition
through S14 can regulate the mitochondrial homeostasis by
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increasing the cAMP levels, as has been recently reviewed
by Di Benedetto et al. [63]. Since mitochondrial dysfunction
is involved in many neurodegenerative diseases and aging
[64], S14 may slow down pathological events in the neurode-
generative process.
Conclusions
In conclusion, our data provide evidence that PDE7 in-
hibition improved hippocampal neurogenesis and mem-
ory by modulating cAMP/pCREB activity and that these
effects may be associated with mitochondrial dynamics
regulation. Considering that S14 treatment has been re-
ported to be beneficial for AD [14] and other neurode-
generative disorders such as Parkinson’s disease [15, 30,
37], this study suggests that S14 is a very promising
disease-modifying drug candidate for the future treat-
ment of neurodegenerative disorders.
Additional file
Additional file 1 Figure S1. Aβ-induced reduction in mitochondrial
biogenesis in neurons is restored after S14 treatment. Mitochondrial mass
was carried out in live rat neuronal primary cultures simultaneously
exposed to 1 μM oligomeric Aβ42 for 24 h and evaluated by confocal
imaging. Representative images showing the mitochondria and the
whole cell body with the range of treatments are presented in the left
panels. Imaging analysis revealed a reduced amount of mitochondrial
volume from the whole cell volume in Aβ42-exposed cells compared to
untreated cells. Treatment with 15 μM S14 on Aβ42-exposed cells
obliterated this effect, showing no changes in the unexposed cells.
Statistical significance was assessed by two-way ANOVA followed by
Fisher’s post-hoc test for multiple comparisons. Data are expressed as
mean ± SEM; n = 4; **p < 0.01; ****p < 0.0001. (JPEG 1623 kb)
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